Eisai Seeks Accelerated Approval for Alzheimer’s Drug Lecanemab
By
Simon Spichak
| September 28th, 2021
The biotechnology company Eisai Co., Ltd. announced a rolling submission for accelerated approval from the Food and Drug Administration for their anti-amyloid Alzheimer’s treatment,…